Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia

The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced new findings from the ongoing real-world IMPACT-TD Registry, reinforcing the positive impact of AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets on individuals living with tardive dyskinesia (TD).

The results, presented at the 2025 Neuroscience Education Institute Fall Congress in Colorado Springs, Colorado, demonstrated that treatment with AUSTEDO or AUSTEDO XR led to meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life.

The interim analysis evaluated 27 adults with TD after three months of treatment using the IMPACT-TD PRO, a 30-question patient-reported outcomes scale measuring the effect of TD across five key life areas. Participants represented a real-world patient population, many living with comorbid psychiatric conditions such as bipolar disorder (41 per cent), anxiety disorder (37 per cent), depression (26 per cent), and schizophrenia (19 per cent).

Patients reported substantial improvement across multiple aspects of daily life, including communication, eating, psychosocial functioning, and activities of daily living. The total motor score on the Abnormal Involuntary Movement Scale (AIMS) showed a mean reduction of 2.9 points, indicating a significant decrease in the severity of involuntary movements consistent with results seen in pivotal clinical trials. Importantly, 85 per cent of participants taking AUSTEDO or AUSTEDO XR alongside their mental health medications reported that their psychiatric conditions remained stable or improved over the same period.

“The silent struggle of tardive dyskinesia, with its relentless, involuntary movements, can rob individuals of independence and quality of life,” said Stacy Finkbeiner, Senior Medical Director, Movement Disorders & Psychiatry at Teva. “These real-world data bring patient experiences to life and further validate clinical findings that AUSTEDO and AUSTEDO XR can meaningfully reduce TD symptoms while supporting mental health stability—core to our mission at Teva of improving the lives of patients.”